160 related articles for article (PubMed ID: 36545700)
1. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
4. Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
El-Hajj Fuleihan G; Drake MT
Metabolism; 2023 Jun; 143():155553. PubMed ID: 37028591
[No Abstract] [Full Text] [Related]
5. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
9. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia.
Fountas A; Andrikoula M; Giotaki Z; Limniati C; Tsakiridou E; Tigas S; Tsatsoulis A
Endocr Pract; 2015 May; 21(5):468-73. PubMed ID: 25667369
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
12. Denosumab for the Treatment of Hypercalcemia in a Patient With Parathyroid Carcinoma: A Case Report.
Roukain A; Alwan H; Bongiovanni M; Sykiotis GP; Kopp PA
Front Endocrinol (Lausanne); 2021; 12():794988. PubMed ID: 35173680
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
14. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
15. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Adhikaree J; Newby Y; Sundar S
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
[No Abstract] [Full Text] [Related]
16. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M; Ishiguro H; Yano I; Toi M
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
[No Abstract] [Full Text] [Related]
17. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
18. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
Størling L; Villadsen GE; Krogh K; Vestergaard P
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
[TBL] [Abstract][Full Text] [Related]
19. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Rajput S; Dutta A; Rajender S; Mithal A; Chattopadhyay N
Front Endocrinol (Lausanne); 2023; 14():1098841. PubMed ID: 36817591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]